C2N Diagnostics Awarded "Fast Track" SBIR by NIA/NIH

December 17, 2009 ST. LOUIS, MO – C2N Diagnostics has received a Fast Track Small Business Innovation Reasearch (SBIR) Award from the National Institute On Aging (NIA), part of the National Institutes of Health (NIH). The award of nearly $1 million will fund milestone-driven research to improve the diagnosis and treatment of Alzheimer’s disease. Dr. Tim West, C2N’s Director of Laboratory Operations, will serve as the study’s principal investigator.

Stated Dr. West, “NIA/NIH’s award provides C2N with funding for an exciting metabolic biomarker initiative that we have underway. This initiative will build upon the existing products we currently offer to our industry collaborators, who are focused on developing promising new therapies to address the global health concern of Alzheimer’s disease and other forms of neurodegeneration.”

About C2N Diagnostics

C2N Diagnostics, LLC formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, the Washington University Office of Technology Management, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). C2N resides at the Center for Emerging Technologies in St. Louis. The company is developing a suite of biomarker assays and tools to assist in pre-clinical drug discovery, clinical drug development, and the early detection and assessment of progression of debilitating neurodegenerative disorders. The company’s first commercial tool, the SILK-Aß™ assay, relies on stable isotope labeling and tandem mass spectrometry for the precise measurement of the kinetics, or in vivo metabolism, of amyloid-beta – a small peptide implicated as a key mediator of Alzheimer’s disease. Other products are in development to target Parkinson’s disease, Huntington’s disease, schizophrenia, and amyotrophic lateral sclerosis (ALS), among others. For additional information, see www.c2ndiagnostics.com or call 1-877-C2N-DIAG (1-877-226-3424).

Acknowledgement and Disclaimer

The project described above was supported by Award Number R44AG034725 from the National Institute On Aging. The content is solely the responsibility of C2N Diagnostics and its authors, and does not necessarily represent the official views of the National Institute On Aging or the National Institutes of Health.